The course and outcome of psychiatric illness in people with Prader-Willi syndrome: Implications for management and treatment

Journal of Intellectual Disability Research

Volumn 51, Issue 1, 2007, Pages 32-42

  Soni, S ^a   Whittington, J ^a   Holland, A J ^a   Webb, T ^b   Maina, E ^b   Boer, H ^c   Clarke, D ^d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^c Janet Shaw Clinic   (United Kingdom)

^d Lea Castle Centre   (United Kingdom)

Author keywords

Imprinting; Medication; Prader Willi syndrome; Psychiatric illness; Psychotic illness

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CITALOPRAM; FLUOXETINE; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; BIPOLAR DISORDER; CONFUSION; DEPRESSION; DEPRESSIVE PSYCHOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; EXTRAPYRAMIDAL SYMPTOM; GENE DELETION; HUMAN; HYPERSALIVATION; LIFE EVENT; MENTAL DISEASE; MUSCLE RIGIDITY; PRADER WILLI SYNDROME; PROGNOSIS; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; QUESTIONNAIRE; RECURRENCE RISK; SEDATION; SIDE EFFECT; TREMOR; UNIPARENTAL DISOMY; UNITED KINGDOM; WEIGHT GAIN;

ADOLESCENT; ADULT; AFFECTIVE DISORDERS, PSYCHOTIC; BIPOLAR DISORDER; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 15; DEPRESSIVE DISORDER; FEMALE; GENETIC SCREENING; HUMANS; MALE; MENTAL RETARDATION; MICROSATELLITE REPEATS; PRADER-WILLI SYNDROME; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; SEROTONIN UPTAKE INHIBITORS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; UNIPARENTAL DISOMY;

EID: 33845294444     PISSN: 09642633     EISSN: 13652788     Source Type: Journal    
DOI: 10.1111/j.1365-2788.2006.00895.x     Document Type: Article

References (35)

1. Abbott Laboratories Limited (2003) Reductil Summary of Product Characteristics. Abbott Laboratories, Maidenhead.
2. Akefeldt A., Ekman R., Gillberg C. & Mansson J. E. (1998) Cerebrospinal fluid monoamines in Prader-Willi syndrome. Biology Psychiatry 44, 1321-8.
3. Beardsmore A., Dorman T. A. C. S. & Webb T. (1998) Affective psychosis and Prader-Willi syndrome. Journal of Intellectual Disability Research 42, 463-71.
4. Benazzi F. (2002) Organic hypomania secondary to sibutramine-citalopram interaction. Journal of Clinical Psychiatry 63, 165.
5. Boer H., Holland A., Whittington J., Butler J., Webb T. & Clarke D. (2002) Psychotic illness in people with Prader Willi syndrome due to chromosome 15 maternal uniparental disomy. Lancet 359, 135-6.
6. Casey D. E. (1993) Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Psychiatric Clinics of North America 16, 589-610.
7. Clarke D., Boer H., Webb T., Scott P., Frazer S., Vogels A., Borghgraef M. & Curfs L. M. (1998) Prader-Willi syndrome and psychotic symptoms: 1. Case descriptions and genetic studies. Journal of Intellectual Disability Research 42, 440-50.
8. Clarke D. J., Kelley S., Thinn K. & Corbett J. A. (1990) Psychotropic drugs and mental retardation: 1. Disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings. Journal of Mental Deficiency Research 34, 385-95.
9. Cohen J. (1998) Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Erlbaum, Hillsdale, NJ.
10. Dech B. & Budow L. (1991) The use of fluoxetine in an adolescent with Prader-Willi syndrome. Journal of the American Academy of Child and Adolescent Psychiatry 30, 298-302.
11. Descheemaeker M. J., Vogels A., Govers V., Borghgraef M., Willekens D., Swillen A., Verhoeven W. & Fryns J. P. (2002) Prader-Willi syndrome: new insights in the behavioural and psychiatric spectrum. Journal of Intellectual Disability Research 46, 41-50.
12. Durst R., Rubin-Jabotinsky K., Raskin S., Katz G. & Zislin J. (2000) Risperidone in treating behavioural disturbances of Prader-Willi syndrome. Acta Psychiatric Scandinavica 102, 461-5.
13. Ebert M. H., Schmidt D. E., Thompson T. & Butler M. G. (1997) Elevated plasma gamma-aminobutyric acid (GABA) levels in individuals with either Prader-Willi syndrome or Angelman syndrome. Journal of Neuropsychiatry and Clinical Neurosciences 9, 75-80.
14. Eichelmann B. (1977) Catecholamines and aggressive behaviour. Neuroregulators and Psychiatric Disorders. Oxford Press, New York, NY.
15. Frances A. J., Kahn D. A., Carpenter D., Docherty J. P. & Donovan S. L. (1998) The Expert Consensus Guidelines for treating depression in bipolar disorder. Journal of Clinical Psychiatry 59 (Suppl. 4), 73-9.
16. Hellings J. A. & Warnock J. K. (1994) Self-injurious behavior and serotonin in Prader-Willi Syndrome. Psychopharmacology Bulletin 30, 245-50.
17. Holland A. J., Whittington J. E., Butler J., Webb T., Boer H. & Clarke D. (2003) Behavioural phenotypes associated with specific genetic disorders: Evidence from a population-based study of people with Prader-Willi syndrome. Psychological Medicine 33, 141-53.
18. Holm V. A., Cassidy S. B., Butler M. G., Hanchett J. M., Greenswag L. R., Whitman B. Y. & Greenberg F. (1993) Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 91, 398-402.
19. Kubota T., Das S., Christian S. L., Baylin S. B., Herman J. G. & Ledbetter D. H. (1997) Methylation-specific PCR simplifies imprinting analysis. Nature Genetics 16, 16-17.
20. Lloyd T., Kennedy N., Fearon P., Kirkbride J., Mallett R., Leff J., Holloway J., Harrison G., Dazzan P., Morgan K., Murray R. M. & Jones P. B. (2005) Incidence of bipolar affective disorder in three UK cities: results from the AESOP study. British Journal of Psychiatry 186, 126-31.
21. McGuffin P., Farmer A. & Harvey I. (1991) A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Archives of General Psychiatry 48, 764-70.
22. Moss S., Goldberg D., Patel P., Prosser H., Ibbotson B., Simpson N. & Rowe S. (1996) The Psychiatric Assessment Schedule for Adults with Developmental Disability (ICD 10 Version). Hester Adrian Research Centre, University of Manchester, Manchester.
23. Nicholls R. D. & Knepper J. L. (2001) Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. Annual Review of Genomics Human Genetics 2, 153-75.
24. Paykel E. S. (1996) The interview for recent life events. Psychological Medicine 27, 301-10.
25. Shapira N. A., Lessig M. C., Murphy T. K., Driscoll D. J. & Goodman W. K. (2002) Topiramate attenuates self-injurious behaviour in Prader-Willi Syndrome. International Journal of Neuropsychopharmacology 5, 141-5.
26. Taflinski T. & Chojnacka J. (2000) Sibutramine-associated psychotic episode. American Journal of Psychiatry 157, 2057-8.
27. Thase M. E. & Sachs G. S. (2000) Bipolar depression: Pharmacotherapy and related therapeutic strategies. Biology Psychiatry 48, 558-72.
28. Verhoeven W. M., Curfs L. M. & Tuinier S. (1998) Prader-Willi syndrome and cycloid psychoses. Journal of Intellectual Disability Research 42, 455-62.
29. Verhoeven W. M., Tuinier S. & Curfs L. M. (2003) Prader-Willi syndrome: The psychopathological phenotype in uniparental disomy. Journal of Medical Genetics 40, e112.
30. Vogels A., Matthijs G., Legius E., Devriendt K. & Fryns J. P. (2003) Chromosome 15 maternal uniparental disomy and psychosis in Prader-Willi syndrome. Journal of Medical Genetics 40, 72-3.
31. Warnock J. K. & Kestenbaum T. (1992) Pharmacologic treatment of severe skin-picking behaviors in Prader-Willi syndrome. Two case reports. Archives of Dermatology 128, 1623-5.
32. Whittaker J. F., Cooper C., Harrington R. C. & Price D. A. (1997) Prader-Willi syndrome and acute psychosis. International Journal of Psychiatry in Clinical Practice 1, 217-19.
33. Whittington J. E., Holland A. J., Webb T., Butler J., Clarke D. & Boer H. (2001) Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. Journal of Medical Genetics 38, 792-8.
34. Williams J., Farmer A. E., Ackenheil M., Kaufmann C. A. & McGuffin P. (1996) A multicentre inter-rater reliability study using the OPCRIT computerized diagnostic system. Psychological Medicine 26, 775-83.
35. World Health Organization (1992) International Statistical Classification of Diseases and Related Health Problems, 1989 Revision. World Health Organization, Geneva.